Education
About Us
Working with TipRanks
Follow Us
Oramed Pharmaceuticals (ORMP)
NASDAQ:ORMP
ORMP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.96 - $3.14
Previous CloseN/A
Volume63.61K
Average Volume (3M)181.02K
Market Cap
$95.14M
Enterprise Value-$23.59M
Total Cash (Recent Filing)$3.43M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)21.7
Beta1.06
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.11
Shares Outstanding40,312,070
10 Day Avg. Volume42,394
30 Day Avg. Volume181,021
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)70.09
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-17.60
Enterprise Value/Ebitda-0.95
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Oramed Pharm News
PremiumCompany Announcements
Oramed Expands with New Facility Acquisition
PremiumCompany Announcements
Oramed Pharm Amends Joint Venture for OraTech Launch
PremiumCompany Announcements
Oramed Pharmaceuticals Reinforces Scilex Financial Ties
---
Bulls Say, Bears Say
Bulls Say
InvestmentThe joint venture will receive a significant capital infusion, with HTIT committing a notable $70M investment, supplemented by a $20M investment from Oramed.
Joint VentureOramed entered into a definitive agreement with HTIT, marking a milestone in the creation of a joint venture centered around Oramed’s cutting-edge oral drug delivery technology.
Bears Say
Clinical EfficacyThe candidates in Oramed's pipeline have yet to show definitive clinical proof-of-concept efficacy.
---
Ownership Overview
13.16% Insiders
0.37% Mutual Funds
15.34% Other Institutional Investors
70.07% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ORMP FAQ
What was Oramed Pharmaceuticals’s price range in the past 12 months?
Oramed Pharmaceuticals lowest stock price was $1.96 and its highest was $3.14 in the past 12 months.
What is Oramed Pharmaceuticals’s market cap?
Oramed Pharmaceuticals’s market cap is $95.14M.
When is Oramed Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Oramed Pharmaceuticals’s earnings last quarter?
Oramed Pharmaceuticals released its earnings results on Jan 11, 2024. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.12 by $0.04.
Is Oramed Pharmaceuticals overvalued?
According to Wall Street analysts Oramed Pharmaceuticals’s price is currently Overvalued.
Does Oramed Pharmaceuticals pay dividends?
Oramed Pharmaceuticals does not currently pay dividends.
What is Oramed Pharmaceuticals’s EPS estimate?
Oramed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oramed Pharmaceuticals have?
Oramed Pharmaceuticals has 40,312,070 shares outstanding.
What happened to Oramed Pharmaceuticals’s price movement after its last earnings report?
Oramed Pharmaceuticals reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.12. Following the earnings report the stock price went down -0.4%.
Which hedge fund is a major shareholder of Oramed Pharmaceuticals?
Currently, no hedge funds are holding shares in ORMP
---
Oramed Pharm Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 12.6%
Last 30 Days ▼ 12.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.23%
12-Months-Change
Fundamentals
Return on Equity
2.92%
Trailing 12-Months
Asset Growth
-28.50%
Trailing 12-Months
Company Description
Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. (ORMP) is a clinical-stage pharmaceutical company focused on the development of innovative oral drug delivery solutions. The company operates primarily in the biotechnology sector, aiming to transform injectable treatments into oral alternatives. Its flagship product is an oral insulin capsule for the treatment of diabetes, which is designed to improve the quality of life for millions of diabetic patients worldwide.
---
ORMP Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---